Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | MDM4 | O15151 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.50 |
| ▸ | CASP3 | P42574 | 2/20 | 0.50 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.50 |
| ▸ | TLR2 | O60603 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29989986 | 1.00 | KMT2A (0.52) | KMT2AMDM4TP53PTPN1CASP3 | |
| SCHEMBL29591196 | 1.00 | KMT2A (0.52) | KMT2AMDM4TP53PTPN1CASP3 | |
| SCHEMBL1709129 | 1.00 | KMT2A (0.52) | KMT2AMDM4TP53PTPN1CASP3 | |
| SCHEMBL30074491 | 1.00 | KMT2A (0.52) | KMT2AMDM4TP53PTPN1CASP3 | |
| SCHEMBL5323666 | 1.00 | KMT2A (0.52) | KMT2AMDM4TP53PTPN1CASP3 | |
| SCHEMBL29792137 | 1.00 | KMT2A (0.52) | KMT2AMDM4TP53PTPN1CASP3 | |
| SCHEMBL7423331 | 1.00 | KMT2A (0.52) | KMT2AMDM4TP53PTPN1CASP3 | |
| SCHEMBL22069879 | 0.96 | PTPN1 (0.49) | KMT2AMDM4TP53PTPN1CASP3 | |
| SCHEMBL20732318 | 0.96 | PTPN1 (0.49) | KMT2AMDM4TP53PTPN1CASP3 | |
| SCHEMBL31133584 | 0.96 | PTPN1 (0.49) | KMT2AMDM4TP53PTPN1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1034 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600759-B2 | Process of preparation of glucagon-like peptide-1 (GLP-1) receptor agonists and their analogs | ENZENE BIOSCIENCES LIMITED (IN) | 2026-04-14 | — | — | US | claimed |
| EP-4602368-A1 | NITRILOTRIACETIC ACID LINKERS, SOLID PHASE SYNTHESIS OF NITRILOTRIACETIC ACID LINKERS AND APPLICATIONS THEREOF | Nicoya Lifesciences Inc. (CA) | 2025-08-20 | — | — | EP | claimed |
| US-20250188019-A1 | COMPOUNDS AND METHODS FOR LIQUID PHASE SYNTHESIS | ELI LILLY AND COMPANY | 2025-06-12 | — | — | US | claimed |
| CN-119350469-B | Method for synthesizing CAGRILINTIDE by large fragment SPPS-LPPS mixing method | 杭州诺澳生物医药科技有限公司 | 2025-05-23 | — | — | CN | claimed |
| US-20250163120-A1 | SOLID PHASE PEPTIDE SYNTHESIS OF INSULIN USING SIDE CHAIN ANCHORED LYSINE | CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) | 2025-05-22 | — | — | US | claimed |
| WO-2025092769-A1 | PREPARATION METHOD FOR DUAL GIP AND GLP-1 RECEPTOR AGONIST | 博瑞生物医药（苏州）股份有限公司 | 2025-05-08 | — | — | WO | claimed |
| CN-119930756-A | Preparation method of dual receptor agonist of GIP and GLP-1 | 博瑞生物医药（苏州）股份有限公司 | 2025-05-06 | — | — | CN | claimed |
| CN-119798407-A | Incretin analogue with multiple biological activities, synthesis method, pharmaceutical composition and application | 江苏食品药品职业技术学院 | 2025-04-11 | — | — | CN | claimed |
| CN-119708196-A | Tenipout peptide synthesis method | 深圳翰宇药业股份有限公司 | 2025-03-28 | — | — | CN | claimed |
| CN-114685645-B | Synthetic method of somalupeptide | 深圳翰宇药业股份有限公司 | 2025-03-21 | — | — | CN | claimed |
| CN-116178214-A | Preparation method of N- (9-fluorenylmethoxycarbonyl) -glutamic acid-1-tert-butyl ester | 吉尔生化（上海）有限公司 | 2023-05-30 | — | — | CN | claimed |
| CN-116120427-A | Synthesis method of semaglutin | 浙江九洲药业股份有限公司 | 2023-05-16 | — | — | CN | claimed |
| WO-2023028466-A1 | COMPOUNDS AND METHODS FOR LIQUID PHASE SYNTHESIS | ELI LILLY AND COMPANY (US) | 2023-03-02 | — | — | WO | claimed |
| CN-114685645-A | Synthetic method of somaglutide | 深圳翰宇药业股份有限公司 | 2022-07-01 | — | — | CN | claimed |
| CN-114560907-A | Preparation method of glutathione impurity | 武汉绿合医药科技有限公司 | 2022-05-31 | — | — | CN | claimed |
| US-20220153804-A1 | PROCESS OF PREPARATION OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS AND THEIR ANALOGS | ENZENE BIOSCIENCES LIMITED (IN) | 2022-05-19 | — | — | US | claimed |
| US-20220143150-A1 | GLUCAGON-LIKE PEPTIDE-1 (GLP-1) AGONIST ANALOG, PROCESS OF PREPARATION AND USES THEREOF | ENZENE BIOSCIENCES LIMITED (IN) | 2022-05-12 | — | — | US | claimed |
| CN-114249808-A | Synthesis method of Cagrilintide | 杭州诺泰澳赛诺医药技术开发有限公司 | 2022-03-29 | — | — | CN | claimed |
| CN-110294800-B | Preparation method of somaglutide | 齐鲁制药有限公司 | 2022-03-04 | — | — | CN | claimed |
| EP-3941936-A2 | PROCESS OF PREPARATION OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS AND THEIR ANALOGS | Enzene Biosciences Ltd. (IN) | 2022-01-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188019-A1 | COMPOUNDS AND METHODS FOR LIQUID PHASE SYNTHESIS | AQP1, CCNB1, CDK2 | KMT2A 2041/4885MDM4 1876/4885TP53 486/4885 |
| US-20250163120-A1 | SOLID PHASE PEPTIDE SYNTHESIS OF INSULIN USING SIDE CHAIN ANCHORED LYSINE | IAPP, INSR, INSRR | KMT2A 278/4885MDM4 4329/4885TP53 3076/4885 |
| US-20220153804-A1 | PROCESS OF PREPARATION OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS AND THEIR ANALOGS | GLP1R, GIPR, GCGR | KMT2A 2767/4885MDM4 3768/4885TP53 3747/4885 |
| US-12600759-B2 | Process of preparation of glucagon-like peptide-1 (GLP-1) receptor agonists and their analogs | GLP1R, GIPR, GCG | KMT2A 2737/4885MDM4 3864/4885TP53 4243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.